ReviewFrontiers in oncology2024
Cardiovascular disease and lung cancer.
Review in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 24 citations in OpenAlex.
- A comprehensive analysis of lung cancer status changes over 10 years: results of Moroccan cohort.BJC reports · 2026Article
- Tumor histologic subtypes and stage impact the risk of cardiovascular diseases death in lung cancer patients after chemotherapy or radiotherapy: a population-based study.Translational cancer research · 2026Article
- Review
- Trends in cardiovascular mortality among lung cancer patients in the United States: a retrospective study from 1999 to 2023.Cardio-oncology (London, England) · 2026Article
- Inflammation mediates platinum-based chemotherapy-induced risk of adverse cardiac events in older NSCLC patients: a pilot study.Cardio-oncology (London, England) · 2026Article
- Unsupervised risk factor identification across cancer types and data modalities via explainable artificial intelligence.NPJ digital medicine · 2026Article
- Trends in the Overall Incidence and Mortality of Lung Cancer: An Extensive Longitudinal Study Utilizing the CDC WONDER Database 1999-2020.Thoracic cancer · 2026Article
- Trends in cardiovascular disease mortality among older adults with co-occuring lung cancer in the United States from 1999 to 2020.BMC cancer · 2026Article
- Temporal trends in the cause of death of patients with colon and rectal cancer.Cancer causes & control : CCC · 2026Article
- A New Era, New Risks: The Cardio-Oncology Perspective on Immunotherapy in Non-Small Cell Lung Cancer.Cancers · 2025Review
- A Tale of Two Periods: The Evolution of Determinants and CVD Mortality Risk in Metastatic NSCLC.Reviews in cardiovascular medicine · 2025Article
- CT-Based Pericardial Composition Change as an Imaging Biomarker for Radiation-Induced Cardiotoxicity.Cancers · 2025Article
- Exploring the protective role of maternal lung cancer history on allergic rhinitis.Journal of clinical biochemistry and nutrition · 2025Article
- Molecular signatures bidirectionally link myocardial infarction and lung cancer.Frontiers in medicine · 2025Article
- Article
- Causes of death and trends in mortality from the year 2000 to 2017 in patients with acute myocardial infarction.Annals of medicine · 2024Article
- Addressing Post-Acute COVID-19 Syndrome in Cancer Patients, from Visceral Obesity and Myosteatosis to Systemic Inflammation: Implications in Cardio-Onco-Metabolism.Biomedicines · 2024Review
- Allostatic Load/Chronic Stress and Cardiovascular Outcomes in Patients Diagnosed With Breast, Lung, or Colorectal Cancer.Journal of the American Heart Association · 2024Article
- Risk factors of osimertinib-related cardiotoxicity in non-small cell lung cancer.Frontiers in oncology · 2024Article
- Case Report: Lung cancer with rare cardiac and other multiple metastases.Frontiers in cardiovascular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the second most common cancer worldwide and the leading cause of cancer-related death. While survival rates have improved with advancements in cancer therapeutics, additional health challenges have surfaced. Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in patients with lung cancer. CVD and lung cancer share many risk factors, such as smoking, hypertension, diabetes, advanced age, and obesity. Optimal management of this patient population requires a full understanding of the potential cardiovascular (CV) complications of lung cancer treatment. This review outlines the common shared risk factors, the spectrum of cardiotoxicities associated with lung cancer therapeutics, and prevention and management of short- and long-term CVD in patients with non-small cell (NSCLC) and small cell (SCLC) lung cancer. Due to the medical complexity of these patients, multidisciplinary collaborative care among oncologists, cardiologists, primary care physicians, and other providers is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.